Member Info for badeli

I am confident that as long as tests achieve the specificity and sensitivity required in particular settings there will never be enough of them available in the UK, Europe, the US and world-wide. Personally I am very pleased whenever I read of another testing breakthrough and do not think any of them threaten NCYT's prospect of ongoing scientific and commercial success. As it happens I think Boris was talking about AVCT's lateral flow test this afternoon but none of know definitively. Every test that can be developed and manufactured will be required for at least a year or two and probably longer so I do not see any issues in terms of space in the market.
Test, test, test, as the WHO said in the spring is going to be our way out of the horrible situation in which so many people find themselves in so many countries. Boris correctly emphasised today that once asymptomatic carriers, as well as those with symptoms, can be identified by any type of test as long as it returns quick and accurate results, then and only then can people live, work and socialise with confidence.

On a personal level I have fairly substantial holdings in NCYT, AVCT, GDR, TILS, ODX and SNG - all will achieve good returns in my view.

No, he did not mention Avacta but did talk about individual testing a lot so I am certain that he was not thinking of the Optigen machines. Lots of different tests will be useful in different ways but today’s emphasis was on testing individuals, or individuals testing themselves, regularly, quickly and accurately using saliva-based tests with one clear objective, namely the identification of carriers, particularly asymptomatic carriers, so that they can self-isolate and not spread the virus, thus allowing everyone else to get on with something much closer to a normal life.

I inferred that he was thinking of Avacta’s test but the name was not mentioned. We do of course have plenty of other circumstantial evidence that Dr Al and Avacta are working with the government but we await public recognition of that.

Another member of the panel at the Press Conference (not sure exactly who she was!) was asked about testing. She reemphasised that they are all looking at new testing technologies which will identify asymptomatic cases very quickly and accurately so that we can use them in Care Homes, hospitals, universities and schools etc. The emphasis seems to have moved from 'we have yet another new test today' to 'we are working really hard to bring forward a real and effective solution created, manufactured and distributed in the UK'. It was made clear that is still a little bit away but 'make no mistake' it is happening.

I believe that the comments this afternoon will be reflected by a new focus in the media on the most likely way out of the very difficult circumstances in which we find ourselves which was emphasised today. Testing will not cure Covid but accurate and fast testing will allow us to begin to get on with our lives. I suggest we continue to get the name Avacta into public consciousness in any way we can. I am sure the media will in any case soon be concentrating on saliva- based tests as the best way forward for individuals in a variety of environments

Having had a few minutes to reflect I am certain Boris was trying to tell us that the cavalry is coming over the hills to save us, and to save the economy. Talked about vaccines, but clearly does not expect one soon, instead said that we will need to rely on a new generation of very fast, very accurate tests. Specifically highlighted, I think for the first time, saliva- based tests and was also at pains to emphasise that the UK is gearing up to manufacture and distribute on an enormous scale for all sorts of clearly-defined groups and to meet various priorities. Mentioned students, children, businesses which need to open etc. He did urge caution about timescale, making it clear that Covid will be with us for some time which is why we must go less quickly than we would wish in order to get it right.

In general, he sounded very enthused and excited and seemed to want to bring real hope to all of us that new tests are our best hope at the moment. I was very left very comfortable that he knows all about Avacta and will have been speaking with Dr Al.

A few more weeks and then ..... watch the price fly!

Press Conference taking place just now - Boris saying 'some of these tests are highly effective - started building infrastructure for manufacturing saliva -based tests in UK ....... and much more besides being . 'We will be able to test students, schoolchildren very regularly, make instant tests available to local authorities etc'

We should be cautious and take the time to get ready, need to build the infrastructure, in time we will use these tests to ensure we can open more businesses etc. We need to work with everyone as we develop the tests.

Strongest hint yet, very confident that we are closing in on very accurate, very quick tests, made and distributed in UK etc.

Sorry this all a bit jumbled, trying to listen and type but very, very promising for AVCT

Hi Fredd1eboy, a blast from the past after all those years on RENE - good to see you are back there as well! I am also in ODX and am very confident. You deserve it to give you a great return!

Hi extrader, we are aware from official company sources that Scott Fletcher has not crossed any new threshold which would require to be announced, that does not mean he has not bought more. He may have done.

This short note is just for the interest of anyone who is new to NCCL and wonders why Scott's appointment as an NED on the Board has generated such interest. Scott has steadily built up a very significant position as a PI in the company and is now the largest shareholder. Almost all his purchases have been on the open market and, even when other PIs were concerned at delays etc, Scott kept buying. Now he has been asked to represent the interests of many LTHs who share his belief in the company and his expectation that we can look forward to a fantastic return on our investments. We couldn't be more pleased and in my view this is a great time, as the price begins to rise again and we enter a period when we are expecting several RNSs, to top up or take a position. Just my opinion but certainly worthy of research.

I do not see a competition among the Covid companies and dislike the sport of share-bashing which does not help anyone in my view - they all have their own USPs and they are all trying to help to control a pandemic. They come and go in terms of share-price depending on the the timing of the release of information but, given that Covid is not going away any time soon, there are several worthy of serious research and potential investment. Most of us did not 'discover' these companies early enough to be able to boast of huge percentage gains but even now they are all likely to reward investors. For what it is worth, I have invested fairly significant sums in 5 companies (largest investment first) over the past three months:

AVCT
NCYT
TILS
ODX
GDR

I imagine I am not alone in having spread my investment and am confident that all will show significant gains over time. There are of course other options which might also do well but I am comfortable and have no interest in criticising investors who see things differently.

mstar, I think you are correct about lawyers dictating the apology for Prof Deeks - when he first tweeted the words were contained inside inverted commas, the tweet was later replaced without punctuation! Perhaps he was trying to make a point the first time or perhaps it was an oversight - either way the words could not be clearer.

Very promising and exciting RNS - there really is the potential to become a significant company once world-wide markets are open to MOS

Ncondezi Energy
@Ncondezi_Energy
· 2h
As the closing date for tendering on the #Malawi / #Mozambique Interconnector draws near Malawi Energy Minister, Bintony Kutsaira's comments remind us of the need for more #power generation in the region to support #economicdevelopment #NCCL #energyforall https://bit.ly/30C8FyF

This interconnecting line is being constructed from right next to where the Ncondezi/CMEC joint mine and power station is to be constructed - this is a really strong national endorsement of the importance of the project to the development of reliable power for the people of Mozambique. We are supported by majors and by governments and approaching an inflection point (probably three!) which will transform Ncondezi's fortunes.

Sounds very positive for the next few weeks!

A message to everyone who is with HL - I find them very good for everything (including very efficient Bed&ISA for whoever asked the question earlier!) EXCEPT live prices for the last few weeks. I contacted them and received this helpful response, although I should point out that this was about three weeks ago and they clearly have not yet resolved the problem! However, I hope this will be helpful for those who are frustrated!

'Thanks for getting in touch.

We’re aware of instances of live prices not updating recently for some stocks.

I hope to assure you we're equally disappointed that this is happening. To provide further detail of the problem, we're currently experiencing an issue with the data we're receiving for live prices. Our live prices are streamed to us from a third party data provider, however once it reaches us the prices don't update as expected. In fact what happens is the prices become static and don't move for some time. We've identified the cause of this is due to certain types of data that's being streamed to us, which is why it only affects a select number of stocks as opposed to every stock on the platform.

When this issue occurs we're able to identify it and begin to work on a short term resolution in means of a workaround to get the prices updating again, however this doesn't prevent the issue from reoccurring.

The overall fix that will prevent further instances is currently underway and is a very high priority with our IT team. It's a large undertaking and as such we don't have any further details at present including any timeframes.

I understand the situation is far from ideal, but I hope I can also assure you that we're taking this incredibly seriously and are doing everything we can to resolve this as quickly as possible.

I apologise for the continued inconvenience this is causing you and thank you for the patience you've shown so far as we're working to fix this.

If you have any further queries, please get back to me.'

A interesting article on the BBC website - it is fine in itself in that it reflects the general belief that 15 minute saliva antigen tests are not reliable enough for the UK to use. The evidence for this is presumably tests which have already been announced which makes it all the more likely that the Avacta test, when details of its reliability are finally published, really will be seen as the Moonshot.

'On-the-spot coronavirus tests – 120 million of them – which give results within minutes are being made available to low- and middle-income countries by the World Health Organization.

One of the tests – the South Korean-made SD BioSensor – is already in use in Italy to screen people at airports.

But these speedy tests are not currently available in the UK.

That’s partly because different countries have different ways of approving tests, and hold them to different standards.

And the UK has generally erred on the side of caution in this arena.

Apart from a natural risk aversion, these very quick tests are considerably less sensitive than the standard test used in the NHS.

That means they pick up fewer cases and tell more people they’re negative when they do in fact have the virus.

For countries that don’t have the infrastructure to run big labs and currently have very little access to any testing at all, these kits could be a game-changer.

The UK is instead focusing its energy on two other rapid tests, which take more like 90 minutes to process than ten and are roughly as sensitive as the standard diagnostic test.'

I was confident before this morning but the presentation has far exceeded my expectations. I believe we are in at the beginning of a very special journey and I will continue to build a position. Timescale is absolutely fine for investors and I have no doubt that the next 6 to 12 months will be very rewarding. Wow, just wow!

Already looking for further manufacturing partners, looking at 5 to 10 million tests per month in the UK alone, but this could easily 'become many tens of million tests per month. There is no doubt in my mind that we could offer many hundreds of millions of tests per month worldwide' . They are already investigating other markets, in particular the Far East at the moment.

Dr Al says he 'is not at all bothered' that there are other antigen tests being produced as the market is absolutely vast - the Avacta technology is of the highest quality with no competitors who can rival the efficacy. The only challenge is to manufacture at huge scale and that is clearly not going to be a problem.

He is clearly very aware, and emphasised this several times, of the commercial opportunity and how closely PIs are watching. He quite clearly is committed to moving everything forward as fast as he can but he will not sacrifice quality for speed. He knows, and made it very clear, that Avacta are onto a world-wide winner and he could not have come across as more quietly confident. There is so much to look forward to and that is without mentioning the incredible work on oncology therapies.

I think it must be you - I am not at all techie and registered and joined as an investor in 30 seconds. I am learning so much and am very impressed.

This is a very substantial achievement and a seminal moment in the development of Angle. Well done to Andrew Newland and his excellent company. He sounds very upbeat and confident.